Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$7.38
+7.7%
$8.66
$56.35
$105.00
$213.91M0.9512,438 shs100,416 shs
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$4.61
+2.4%
$0.00
$2.88
$26.62
$165.27MN/A244,073 shs107,724 shs
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$0.64
C$0.64
C$0.38
C$8.17
C$90.27MN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$19.75
+0.7%
$20.31
$2.03
$14.36
$32.80M1.1150,104 shs51,034 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00%+0.41%-15.30%+0.55%-88.81%
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
+1.35%+0.90%-5.46%+449,999,900.00%+449,999,900.00%
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.00%0.00%0.00%0.00%0.00%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00%-6.63%-11.77%+9.26%-45.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/AN/AN/AN/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00
N/AN/AN/A
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
0.00
N/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.00
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$3.86M42.78N/AN/A$8.22 per share0.56
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$35.22M2.56N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$71.11MN/A0.00N/AN/A-25.39%-23.22%N/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
-C$10.46MN/A0.00N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A

Latest CTST, AVTE, NLTX, and BIOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$0.56-$0.60-$0.04-$0.60N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
13.21
13.21
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.03%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%

Insider Ownership

CompanyInsider Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
24.90%
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
20.82%
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A35.85 million28.39 millionN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
576141.49 millionN/AOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$7.38 +0.53 (+7.74%)
As of 08/21/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

BioAge Labs stock logo

BioAge Labs NASDAQ:BIOA

$4.61 +0.11 (+2.44%)
As of 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

CannTrust stock logo

CannTrust NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$19.75 +0.14 (+0.71%)
As of 08/21/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.